Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for sickle cell disease (SCD).[1][1]–[4][2] Several barriers prevent its widespread application, including the lack of a suitable donor, risk of early and late onset of regimen-related toxicities, rejection